GlassScriptPhysician profile
Larissa Deblanc
NPI 1083154330
$2,914.62
in general payments reported to CMS, 2019-2025
23 companies · $14.85 in 2025
The $14.85 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $883 · 2023: $934 · 2024: $136 · 2025: $14.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $640.38 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $452.31 | 2021-2024 | Ingrezza |
| Gilead Sciences, INC. | $291.03 | 2021-2023 | Epclusa |
| Abbvie INC. | $222.34 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $174.42 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Biotech, INC. | $145.91 | 2021-2023 | Symtuza |
| Janssen Products, LP | $99.99 | 2021 | |
| Viiv Healthcare Company | $87.88 | 2021 | |
| Idorsia Pharmaceuticals US INC | $85.80 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $83.46 | 2021 | |
| Alkermes, INC. | $74.58 | 2023 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $65.90 | 2022-2023 | Jornay Pm |
| Indivior INC. | $60.05 | 2022-2023 | Perseris |
| Otsuka America Pharmaceutical, INC. | $57.46 | 2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Novo Nordisk INC | $57.10 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $51.40 | 2022-2023 | Adzenys Xr-Odt |
| Lundbeck LLC | $49.42 | 2022 | |
| Theratechnologies INC. | $47.81 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $41.60 | 2022 | |
| Vanda Pharmaceuticals INC. | $38.43 | 2023 | Fanapt, Hetlioz |
| Corium, LLC | $37.93 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $33.48 | 2023 | Invega Sustenna, Invega Trinza |
| Emd Serono, INC. | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Deblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.